- Home
- ILPT vs RLMD Comparison
ILPT vs RLMD Comparison
Compare ILPT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILPT | RLMD |
|---|---|---|
| Founded | 2017 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.9M | 461.9M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ILPT | RLMD |
|---|---|---|
| Price | $7.27 | $3.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $7.05 | ★ $12.40 |
| AVG Volume (30 Days) | 265.1K | ★ 1.2M |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | 31.51 | ★ 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $13,070.00 |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $2.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $4.92 | $1.80 |
| 52 Week High | $9.43 | $8.00 |
Technical Indicators
Market Signals| Indicator | ILPT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 26.58 | 33.01 |
| Support Level | $5.21 | $3.59 |
| Resistance Level | $9.29 | $4.51 |
| Average True Range (ATR) | 0.19 | 0.22 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 6.25 | 16.67 |
Price Performance
Historical ComparisonAbout ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.